Benzinga · Oct 5, 2026
IM
NASDAQ · IMNM
Immunome, Inc.
Healthcare · Biotechnology
$21.17
Down-$1.86 (-8.79%)
Updated Oct 7, 2026, 1:51 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.79B
- P/E ratio
- -7.98
- Dividend yield
- 0.00%
- 52-week range
- $17.83 – $30.06
- Volume
- 1.22M
- Avg. volume
- 1.51M
Price performance · IMNM
IMNM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
IMNM closed at $21.17 after 20 trading sessions, down 21.04% for the selected period.
- Last close
- $21.17
- Period change
- -21.04%
- Period low
- $20.89
- Period high
- $26.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $20.79 | $21.48 | $20.67 | $21.17 | 1.22M |
| Oct 2, 2026 | $21.33 | $21.46 | $20.815 | $20.90 | 1.17M |
| Oct 1, 2026 | $21.17 | $21.49 | $20.71 | $20.89 | 1.1M |
| Sep 30, 2026 | $22.15 | $22.555 | $21.51 | $21.51 | 1.31M |
| Sep 29, 2026 | $21.64 | $22.0105 | $21.355 | $21.89 | 917.01K |
| Sep 28, 2026 | $21.24 | $21.81 | $20.845 | $21.68 | 945.21K |
| Sep 25, 2026 | $22.43 | $22.65 | $21.15 | $21.41 | 2.42M |
| Sep 24, 2026 | $24.24 | $24.34 | $22.205 | $22.34 | 2.7M |
| Sep 23, 2026 | $25.88 | $25.94 | $24.035 | $24.24 | 2.27M |
| Sep 22, 2026 | $25.17 | $25.81 | $25.085 | $25.75 | 1.06M |
| Sep 21, 2026 | $24.63 | $25.255 | $24.19 | $25.07 | 1.18M |
| Sep 18, 2026 | $24.01 | $24.24 | $23.355 | $23.97 | 3.96M |
| Sep 17, 2026 | $24.10 | $24.64 | $23.77 | $23.93 | 890.86K |
| Sep 16, 2026 | $24.29 | $24.75 | $23.36 | $23.46 | 1.32M |
| Sep 15, 2026 | $24.44 | $24.475 | $23.55 | $23.95 | 1.33M |
| Sep 14, 2026 | $24.65 | $25.26 | $24.40 | $24.55 | 744.61K |
| Sep 11, 2026 | $25.32 | $25.73 | $24.60 | $24.67 | 692.56K |
| Sep 10, 2026 | $25.69 | $26.08 | $24.91 | $24.97 | 729.87K |
| Sep 9, 2026 | $26.43 | $26.99 | $26.10 | $26.12 | 784.12K |
| Sep 8, 2026 | $26.15 | $27.245 | $25.91 | $26.81 | 828.62K |
Latest IMNM news
The latest Smart Investors Daily articles mentioning IMNM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IMNM research
Overview
Company profile and research snapshot.
Company profile
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Stifel | Hold | — |
| Sep 21, 2026 | Alliance Global Partners | Buy | — |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
News briefing
Generated Oct 6, 2026, 9:15 PM
Why Is IMNM Down Today?
Immunome, Inc. (IMNM) is experiencing a significant decline of $1.86 per share, or 8.79%, though the available news remains limited. The stock appears to be caught up in broader market volume movements, suggesting the sell-off may be driven by technical factors or sector-wide headwinds rather than company-specific catalysts.
Bottom line: IMNM's 8.79% decline appears driven primarily by volume momentum and technical factors rather than negative company-specific news, creating an uncertain near-term outlook. Investors should monitor for upcoming catalysts, clinical developments, or sector trends while remaining cautious until clearer drivers of the sell-off emerge.
Yahoo · Oct 2, 2026
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
Immunome, Inc. recently reported that the FDA cleared its Investigational New Drug application for IM-1340, a potential first-in-class antibody-drug conjugate for advanced solid tumors, enabling the company to begin a Phase 1 trial focused on safety, tolerability, pharmacokinetics, and early anti-tumor activity. By pairing a transport receptor broadly expressed across solid tumors with its proprietary HC74 topoisomerase I inhibitor payload, Immunome is adding another differentiated oncology...
Yahoo · Oct 1, 2026
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues
Immunome has delivered a powerful multi year share price run, and the question now is whether the current US$21.51 price lines up with the cash flows that can support it. With the spotlight on its pipeline progress, the valuation story increasingly comes back to what the company’s future cash generation may justify. Immunome’s share price has gained 186.4% over the past 3 years, which puts a lot of weight on whether its cash flows can eventually back up that kind of move. The recent FDA...
Benzinga · Oct 1, 2026
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24
Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and announces Price Target of $24.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
